Literature DB >> 14640040

Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan.

Gen Sobue1, Haruki Koike, Ken-ichiro Misu, Naoki Hattori, Masahiko Yamamoto, Shu-ichi Ikeda, Yukio Ando, Masamitsu Nakazato, Akira Inukai.   

Abstract

Type I (transthyretin Val30Met) familial amyloid polyneuropathy (FAP ATTR Val30Met) has been reported in relation to two endemic foci in Japan. These cases are characterized by a relatively young age at onset, between the second and third decade, high penetrance rate, concentration in endemic foci, predominant loss of superficial sensation, severe autonomic dysfunction, and atrioventricular nodal block requiring pacemaker implantation. In contrast to these endemic cases, because of advances in DNA diagnosis, late-onset cases of FAP ATTR Val30Met with symptoms appearing at or over 50 years of age are now recognized to occur widely throughout Japan. These cases have a male preponderance, low penetrance rate, no relationship to endemic foci, sensorimotor symptoms beginning distally in the lower extremities with disturbance of both superficial and deep sensation, and relatively mild autonomic symptoms. This type of FAP ATTR Val30Met has been overlooked because its clinical and genetic features differ from those of "typical" early-onset cases. Anticipation of age at onset is known to occur in pedigrees from the two endemic foci in Japan, with age at onset becoming younger in patients of successive generations. On the other hand, age at onset of patients in late-onset families seems to be uniformly late among the patient siblings when family history is present. Pathologic findings of the peripheral nervous system also differ in accordance with differences of clinical features. Loss of dorsal root and sympathetic ganglion neurons was severe in the early-onset cases, whereas it was only mild to moderate in the late-onset cases. Unmyelinated fibers in the biopsied sural nerve specimens of late-onset cases seemed to be relatively well preserved compared to those of previously reported early-onset cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14640040

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

1.  Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?

Authors:  Ioannis Petrakis; Vasiliki Mavroeidi; Kostas Stylianou; George Efthymiou; Kostas Perakis; Eleftheria Vardaki; Spyridon Stratigis; Kostas Giannakakis; Kostas Kourouniotis; George Amoiridis; Andreas Plaitakis; Maria Joao Saraiva; Ken Ichi Yamamura; Eugene Daphnis
Journal:  Transgenic Res       Date:  2012-07-18       Impact factor: 2.788

2.  Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments.

Authors:  Takaki Taniguchi; Masahiro Ando; Yuji Okamoto; Akiko Yoshimura; Yujiro Higuchi; Akihiro Hashiguchi; Nozomu Matsuda; Mamoru Yamamoto; Eisuke Dohi; Makoto Takahashi; Masanao Yoshino; Taichi Nomura; Masaaki Matsushima; Ichiro Yabe; Yui Sanpei; Hiroyuki Ishiura; Jun Mitsui; Masanori Nakagawa; Shoji Tsuji; Hiroshi Takashima
Journal:  J Hum Genet       Date:  2022-01-14       Impact factor: 3.172

3.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

4.  (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Authors:  Björn Pilebro; Ole B Suhr; Ulf Näslund; Per Westermark; Per Lindqvist; Torbjörn Sundström
Journal:  Ups J Med Sci       Date:  2016-02-05       Impact factor: 2.384

Review 5.  Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.

Authors:  Yoshiki Sekijima; Mitsuharu Ueda; Haruki Koike; Sonoko Misawa; Tomonori Ishii; Yukio Ando
Journal:  Orphanet J Rare Dis       Date:  2018-01-17       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.